TORONTO, March 19, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025.
At the Meeting, shareholders elected the following nominees to the board of directors:
- Michael Frank, Chief Executive Officer
- Joshua Herman, Independent Director
- Andrew Lindzon, Independent Director
- William Jackson, Independent Director
- Christian Scovenna, Independent Director
Shareholders also approved:
- The appointment of Horizon Assurance LLP, Chartered Professional Accountants, as the auditor of the Company for the ensuing fiscal year
- Authorization for the directors to fix the remuneration paid to the auditor
- A resolution authorizing the continuation of Company’s 10% rolling incentive stock option plan for the ensuing year
In light of feedback from shareholders, the Board of Directors decided not to proceed with the proposal to amend of the Company’s articles of incorporation to consolidate its outstanding Common Shares.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com